Basilea reports new prevalence data for EB1, a potential response-predictive biomarker for lisavanbulin in glioblastoma and other tumor types, at ASCO Annual Meeting

NEXT STORY
Updated Recommendations from the World Health Organization Further Support Use of Ebola Vaccine Regimen from Johnson & Johnson and Bavarian Nordic
PREV STORY
AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aegea Biotechnologies, Inc. and Tauriga Sciences Inc. Announce Progress on the Development of Rapid, Lateral Flow Point-of-Care COVID-19 Diagnostic Test 

author_avatar
NASDAQ Market News

CoLabs Announces Regulation A+ Stock Offering in its Reimagined Skincare Delivery Technology QuantaSphere® and Growing Business

author_avatar
NASDAQ Market News

Devimistat (CPI-613®) to be Explored in a New Combination for T-Cell Lymphoma Treatment as Part of Stand Up To Cancer’s T-Cell Lymphoma “Dream Team Research Grant”

This study will be conducted under the ‘Tailoring CAR-based immunotherapy strategies to T-Cell Lymphoma’ ...

author_avatar
NASDAQ Market News